Published on : Jul 26, 2017
Tetraphase Pharmaceuticals Inc. has announced on Tuesday that one of its antibiotics has succeeded the phase 3 clinical trial evaluating its safety and efficacy for the treatment of the highly complicated intra-abdominal infections. The results of the 500-patient trial reveal that the antibiotic, called eravacycline, has no serious side effects and is at least as effective as other commonly prescribed antibiotics to treat the condition.
The company, a clinical stage biopharmaceutical firm with focus on the development of new antibiotic varieties to treat complex multidrug-resistant bacterial infections, plans to get the antibiotic FDA approved early next year. In Europe, the company plans to file for approval in the third quarter of 2017.
Guy MacDonald, Tetraphase’s CEO, said that the antibiotic has the potential to play a big role in the treatment of several nosocomial infections. Following the news, the company witnessed a 22% rise in its shares in after-hour trading. If the gains are consistent, the company could witness a massive rise in its market cap.
The company has also begun the stage 3 trial of eravacycline for complicated urinary tract infections. In 2015, an earlier phase 3 trial of the antibiotic for patients with the condition had failed, leading to a significant drop in the company’s stock.
The company was formed in 2006 and became public in 2013. In March, the company garnered funds worth US$4mn over 18 months from CARB-X, a Boston-based accelerator program that invests in companies developing life-saving antibacterial drugs.